Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803902 | 0.79 | HTT (0.48) | ADRB2ADRB1LMNASMN1; SMN2 | |
| SCHEMBL2328627 | 0.78 | AR (0.54) | AR | |
| SCHEMBL6360882 | 0.72 | AR (0.61) | ARKDM4ELMNA | |
| SCHEMBL27616363 | 0.72 | ABCB1 (0.53) | ARABCB1 | |
| SCHEMBL2328945 | 0.71 | ADRB2 (0.56) | ADRB2ADRB1KDM4ELMNACYP1A2 | |
| SCHEMBL2361312 | 0.71 | ADRB2 (0.56) | ADRB2ADRB1KDM4ELMNACYP1A2 | |
| SCHEMBL2331246 | 0.71 | ADRB2 (0.56) | ADRB2ADRB1KDM4ELMNACYP1A2 | |
| SCHEMBL764884 | 0.71 | ADRB2 (0.55) | ADRB2ADRB1LMNA | |
| SCHEMBL29818847 | 0.71 | ADRB2 (0.45) | ADRB2ADRB1 | |
| SCHEMBL10720250 | 0.71 | CYP2D6 (0.39) | ADRB2ADRB1ABCB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227474-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100144661-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-6858615-B2 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | PARION SCIENCES, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | PARION SCIENCES, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | CYFI, INC. (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ADRB2 173/4885ADRB1 183/4885AR 3361/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | ADRB2 337/4885ADRB1 291/4885AR 2915/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ADRB2 173/4885ADRB1 183/4885AR 3361/4885 |
| US-20040229884-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | SCNN1B, KCNN2, SCNN1G | ADRB2 159/4885ADRB1 254/4885AR 3063/4885 |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | ADRB2 1/4885ADRB1 4/4885AR 1164/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ADRB2 173/4885ADRB1 183/4885AR 3361/4885 |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | ADRB2 239/4885ADRB1 304/4885AR 4089/4885 |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | AQP1, TRPV1, AQP3 | ADRB2 106/4885ADRB1 161/4885AR 3951/4885 |
| US-20100144661-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN5A, SCN2B | ADRB2 150/4885ADRB1 180/4885AR 3653/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ADRB2 173/4885ADRB1 183/4885AR 3361/4885 |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | SCNN1B, KCNN2, KCNN1 | ADRB2 202/4885ADRB1 485/4885AR 3901/4885 |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | HRH4, HRH2, HRH1 | ADRB2 16/4885ADRB1 19/4885AR 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.